

SANOFI-AVENTIS  
Form 6-K  
September 09, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

□□□□□□□□

**FORM 6-K  
REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

□□□□□□□□

For the month of September 2005

Commission File Number: 001-31368

**SANOFI-AVENTIS**

(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F    Form 40-F  
x                    o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o                    No x

If  Yes  marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_

On September 6 and 9, 2005, sanofi-aventis issued the press releases attached hereto as Exhibits 99.1 and 99.2, which are incorporated herein by reference.

**Exhibit List**

Edgar Filing: SANOFI-AVENTIS - Form 6-K

| <u>Exhibit No.</u> | <u>Description</u>                                                                                               |
|--------------------|------------------------------------------------------------------------------------------------------------------|
| Exhibit 99.1       | Press Release dated September 6, 2005, concerning program evaluating clopidogrel                                 |
| Exhibit 99.2       | Press Release dated September 9, 2005, concerning FDA advisory committee recommendation with respect to Exubera® |

2

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 9, 2005

SANOFI-AVENTIS

By: /s/ Patricia Kodyra

Name: Patricia Kodyra

Title: Associate Vice President

Financial and Securities Law

3

---

**Exhibit List**

| <u>Exhibit No.</u> | <u>Description</u>                                                                                               |
|--------------------|------------------------------------------------------------------------------------------------------------------|
| Exhibit 99.1       | Press Release dated September 6, 2005, concerning program evaluating clopidogrel                                 |
| Exhibit 99.2       | Press Release dated September 9, 2005, concerning FDA advisory committee recommendation with respect to Exubera® |

4

---